Shared on03 Oct 25Fair value Increased 3.85%
United Therapeutics' analyst price target has climbed significantly, rising from approximately $467 to nearly $485 per share. Analysts cite robust Phase 3 results for Tyvaso in idiopathic pulmonary fibrosis and a strengthened outlook for future sales growth.
Shared on18 Sep 25Fair value Increased 2.19%
Analysts raised their price target for United Therapeutics to $466.82, citing strong TETON-2 Phase 3 data for Tyvaso in IPF that de-risk future revenue, support peak sales projections, and heighten confidence in market exclusivity and regulatory approvals. Analyst Commentary Bullish analysts raised price targets significantly following strong Phase 3 TETON-2 data for Tyvaso in idiopathic pulmonary fibrosis (IPF), with the drug meeting primary and key secondary endpoints and demonstrating competitive, clinically meaningful efficacy.
Shared on03 Sep 25Fair value Increased 20%
United Therapeutics’ consensus price target has been raised from $380.57 to $399.90, reflecting heightened analyst optimism following positive Phase 3 TETON-2 Tyvaso IPF results that signal a multibillion-dollar sales opportunity and improved revenue outlook despite competitive and litigation risks. Analyst Commentary Bullish analysts increased price targets sharply following "surprisingly positive" Phase 3 TETON-2 results for Tyvaso in idiopathic pulmonary fibrosis (IPF), citing clinically meaningful FVC benefit, strong statistical significance, and a competitive efficacy profile compared to pipeline peers.
Shared on30 Apr 25Fair value Decreased 1.71%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25Fair value Decreased 1.33%
AnalystConsensusTarget has decreased shares outstanding growth rate from 0.0% to 0.0%.
Shared on16 Apr 25Fair value Increased 0.69%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 6.34%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 0.27%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 0.75%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Increased 3.43%
AnalystConsensusTarget has decreased revenue growth from 9.4% to 7.2%.